These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. Stephenson KE; Keefer MC; Bunce CA; Frances D; Abbink P; Maxfield LF; Neubauer GH; Nkolola J; Peter L; Lane C; Park H; Verlinde C; Lombardo A; Yallop C; Havenga M; Fast P; Treanor J; Barouch DH PLoS One; 2018; 13(11):e0205139. PubMed ID: 30427829 [TBL] [Abstract][Full Text] [Related]
4. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Krougliak V; Graham FL Hum Gene Ther; 1995 Dec; 6(12):1575-86. PubMed ID: 8664382 [TBL] [Abstract][Full Text] [Related]
5. A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products. Haut LH; Gill AL; Kurupati RK; Bian A; Li Y; Giles-Davis W; Xiang Z; Zhou XY; Ertl HC Hum Gene Ther Methods; 2016 Oct; 27(5):187-196. PubMed ID: 27604324 [TBL] [Abstract][Full Text] [Related]
6. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. Brough DE; Lizonova A; Hsu C; Kulesa VA; Kovesdi I J Virol; 1996 Sep; 70(9):6497-501. PubMed ID: 8709289 [TBL] [Abstract][Full Text] [Related]
7. Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches. Murakami P; Havenga M; Fawaz F; Vogels R; Marzio G; Pungor E; Files J; Do L; Goudsmit J; McCaman M J Virol; 2004 Jun; 78(12):6200-8. PubMed ID: 15163713 [TBL] [Abstract][Full Text] [Related]
8. Laboratory-Scale Production of Replication-Deficient Adenovirus Vectored Vaccines. Morris SJ; Turner AV; Green N; Warimwe GM Methods Mol Biol; 2016; 1349():121-35. PubMed ID: 26458833 [TBL] [Abstract][Full Text] [Related]
9. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII. Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775 [TBL] [Abstract][Full Text] [Related]
10. Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli. Hoffmann D; Wildner O BMC Biotechnol; 2006 Aug; 6():36. PubMed ID: 16887042 [TBL] [Abstract][Full Text] [Related]
11. Characterization of human adenovirus 35 and derivation of complex vectors. McVey D; Zuber M; Ettyreddy D; Reiter CD; Brough DE; Nabel GJ; King CR; Gall JG Virol J; 2010 Oct; 7():276. PubMed ID: 20959004 [TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. Hehir KM; Armentano D; Cardoza LM; Choquette TL; Berthelette PB; White GA; Couture LA; Everton MB; Keegan J; Martin JM; Pratt DA; Smith MP; Smith AE; Wadsworth SC J Virol; 1996 Dec; 70(12):8459-67. PubMed ID: 8970968 [TBL] [Abstract][Full Text] [Related]
13. IIIa deleted adenovirus as a single-cycle genome replicating vector. Crosby CM; Barry MA Virology; 2014 Aug; 462-463():158-65. PubMed ID: 24996029 [TBL] [Abstract][Full Text] [Related]
14. Induction of systemic and mucosal immune responses in cotton rats immunized with human adenovirus type 5 recombinants expressing the full and truncated forms of bovine herpesvirus type 1 glycoprotein gD. Mittal SK; Papp Z; Tikoo SK; Baca-Estrada ME; Yoo D; Benko M; Babiuk LA Virology; 1996 Aug; 222(2):299-309. PubMed ID: 8806514 [TBL] [Abstract][Full Text] [Related]
15. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394 [TBL] [Abstract][Full Text] [Related]
16. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Fallaux FJ; Bout A; van der Velde I; van den Wollenberg DJ; Hehir KM; Keegan J; Auger C; Cramer SJ; van Ormondt H; van der Eb AJ; Valerio D; Hoeben RC Hum Gene Ther; 1998 Sep; 9(13):1909-17. PubMed ID: 9741429 [TBL] [Abstract][Full Text] [Related]
17. Development of oncolytic and gene therapy vectors based on adenovirus serotype 4 as an alternative to adenovirus serotype 5. Sallard E; Schulte L; van den Boom A; Klimovitskii A; Knierer J; Hagedorn C; Knocks M; Zhang W; Kreppel F; Ehrhardt A; Ehrke-Schulz E J Gene Med; 2024 Jan; 26(1):e3576. PubMed ID: 37580111 [TBL] [Abstract][Full Text] [Related]
18. Human adenovirus type 5 vectors deleted of early region 1 (E1) undergo limited expression of early replicative E2 proteins and DNA replication in non-permissive cells. Saha B; Parks RJ PLoS One; 2017; 12(7):e0181012. PubMed ID: 28700677 [TBL] [Abstract][Full Text] [Related]
19. Protease-deleted adenovirus as an alternative for replication-competent adenovirus vector. Elahi SM; Nazemi-Moghaddam N; Gilbert R Virology; 2023 Sep; 586():67-75. PubMed ID: 37487327 [TBL] [Abstract][Full Text] [Related]
20. Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. Custers J; Kim D; Leyssen M; Gurwith M; Tomaka F; Robertson J; Heijnen E; Condit R; Shukarev G; Heerwegh D; van Heesbeen R; Schuitemaker H; Douoguih M; Evans E; Smith ER; Chen RT; Vaccine; 2021 May; 39(22):3081-3101. PubMed ID: 33676782 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]